Helius Medical Techの空売り状況は、投資家がHelius Medical Techの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Helius Medical Tech (NASDAQ:HSDT) 株価情報, 空売り情報

Helius Medical Tech

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Technologies Inc

Helius Medical Technologies Inc Warrants (02/02/2026)

Guggenheim analyst John Difucci reiterates Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) from Neutral to Neutral.

News

Reiteration

Analyst Ratings

WDAY

Guggenheim Reiterates Neutral on Workdayto Neutral

Barclays analyst Adrienne Yih maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Overweight and raises the price target from $73 to $80.

Price Target

URBN

Barclays Maintains Overweight on Urban Outfitters, Raises Price Target to $80

Stifel analyst Brad Reback maintains Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Hold and lowers the price target from $310 to $275.

Stifel Maintains Hold on Workday, Lowers Price Target to $275

Some billionaires tip 10% and call it a lesson in humility. Shaquille O'Neal? He'll pay your rent—if you bring the food fast enough.
Despite a net worth reportedly <a href="https://www.benzinga.com/personal-finance/25/03/44380108/trust-me-im-reading-what-hes-doing-every-day-nba-legend-shaq-with-a-500-million-net-worth-swears-by-warren-buffetts-investing-wisdom">hovering around $500 million</a> and a portfolio that includes Krispy Kreme, early investments in Google and Ring, and more than a few real estate plays, Shaq isn't known for flaunting his wealth. He's known for sharing it.
Back in 2017, during an <a href="https://youtu.be/J_8YDZ0rbnU?si=sI_VPDeMYj9YLEBc">interview on "Jimmy Kimmel Live,"</a> Shaq explained his unconventional approach to tipping—and it's very on brand.
"When I'm at restaurants, I am a big tipper," he said. "I like to show my appreciation."
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
And that appreciation starts before the food even hits the table.
"So when they come up to the table," he told host Jimmy Kimmel, "I say, the quicker I get my order, the bigger your tip will be. And the food will come fast."
It works. And once the meal's done?
"I'll ask them, how much you want?" Shaq said casually.
That response caught Kimmel off guard. "You'll ask the waiter how much they want?"
Usually the tip is up to the diner—not the server. But Shaq doesn't exactly play by the usual rules. And once, that unexpected offer came with a big ask.
"The most someone said was $4,000," Shaq said. "And I said, ‘OK, no problem.'"
Stunned, Kimmel questioned, "You gave them $4,000?"
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
Shaq grinned. "It was a young lady. She goes, oh my God, you're gonna pay my rent for two months."
Kimmel laughed, warning him that kind of generosity might backfire. "You really should not have said this, because now you can never go out to dinner again."
And he had a point—now that word's out he's not just a generous tipper, but the kind who lets waitstaff name their price.
Of course, this isn't a one-off. Shaq's done things like buy an <a href="https://www.benzinga.com/personal-finance/25/01/43077262/nba-legend-shaq-spotted-a-young-man-buying-an-engagement-ring-in-zales-when-he-swooped-in-and-paid-for-it-tell-your-girlfriend-i-got-it">engagement ring for a young man</a>, pay off the tab for an entire restaurant, and even help the homeless get back on their feet. Stories of his kindness are easy to find—and usually go viral.
But when it comes to his own kids? He makes them work for it.
See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
In a 2021 appearance on the "<a href="https://youtu.be/XByJpQzl2DY?si=MMLbn0CyGwpvr4H_">Earn Your Leisure</a>" podcast, Shaq laid out the difference:
"My kids are older now. They're kinda upset with me. They're not really upset, but they don't understand. I tell them all the time: <a href="https://www.benzinga.com/personal-finance/24/09/40943843/we-aint-rich-im-rich-nba-legend-shaq-says-his-daughters-and-sons-dont-get-equal-treatment-my-boy">‘We ain't rich. I'm rich.'"</a>
He went on: "You got to have a bachelor's or master's degree, and then, if you want me to invest in one of your companies, <a href="https://www.benzinga.com/personal-finance/25/03/44319385/shaq-makes-his-6-kids-pitch-a-business-plan-if-they-want-cash-you-want-me-to-be-the-bank-im-gonna-do-exactly-what-the-bank-is-going-to-do">you're going to have to present it to me</a>. Bring it to me, and I'll let you know. I'm not giving you nothing."
He may leave four-figure tips for strangers, but for his kids? It's all about hustle, discipline, and a pitch deck.
Read Next:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Shaquille O' Neal Says A Young Waitress Once Asked Him For A $4,000 Tip To Pay Her Rent For Two Months — And He Said, 'Ok, No Problem'

Guggenheim analyst Michael Schmidt maintains UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) with a Buy and lowers the price target from $40 to $15.

URGN

Guggenheim Maintains Buy on UroGen Pharma, Lowers Price Target to $15

Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) has outperformed the market over the past 5 years by 37.19% on an annualized basis producing an average annual return of 51.26%. Currently, Vistra has a market capitalization of $52.99 billion. 
Buying $1000 In VST: If an investor had bought $1000 of VST stock 5 years ago, it would be worth $7,918.86 today based on a price of $156.16 for VST at the time of writing.
<h3>Vistra's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748011511_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Vistra Stock In The Last 5 Years

Barclays analyst Brian Morton maintains Toronto-Dominion Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TD#TSX">TD</a>) with a Underweight and raises the price target from C$81 to C$83.

TSX:TD

Barclays Maintains Underweight on Toronto-Dominion Bank, Raises Price Target to C$83

Stifel analyst Tore Svanberg maintains Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) with a Buy and raises the price target from $35 to $42.

SMTC

Stifel Maintains Buy on Semtech, Raises Price Target to $42

WIIM

DECK

Deckers Outdoor shares are trading lower after the company issued weak Q1 guidance and said it is not providing FY26 outlook given macroeconomic uncertainty related to evolving global trade policies.

Stifel analyst Steven Wieczynski maintains OneSpaWorld Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSW#NASDAQ">OSW</a>) with a Buy and raises the price target from $21 to $23.

Stifel Maintains Buy on OneSpaWorld Hldgs, Raises Price Target to $23

Barclays analyst Adrienne Yih maintains Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) with a Overweight and lowers the price target from $157 to $156.

ROST

Barclays Maintains Overweight on Ross Stores, Lowers Price Target to $156

Archer-Daniels-Midland Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) shares fell 1.1% to $47.42 Friday morning following renewed fears of a U.S.-EU trade war. The decline came after President Donald Trump <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45585283/trump-tariff-threat-hits-europe-stocks-sink-as-50-duties-loom">proposed</a> a sweeping 50% tariff on all European Union imports, igniting investor concern over potential retaliatory measures that could target American agricultural exports.
What To Know: ADM, a global agribusiness powerhouse, relies heavily on international trade to move its soybeans, corn and processed food ingredients. 
Europe represents a <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45585283/trump-tariff-threat-hits-europe-stocks-sink-as-50-duties-loom">significant export market</a> for ADM&#8217;s commodities and bio-based products and any retaliatory EU tariffs could sharply restrict market access for U.S. agricultural firms. 
Moreover, the uncertainty threatens to disrupt supply chains and weigh on crop prices, two factors that directly impact ADM&#8217;s margins.
The tariff threat arrives at a delicate moment for global trade, with slowing growth already pressuring commodity markets. ADM's global footprint, particularly in grain trading and oilseed processing, makes it vulnerable to geopolitical trade shifts. 
Investors appear to be pricing in the risk of a tit-for-tat tariff escalation that could hurt U.S. exporters like ADM more than European firms.
Read Also: <a href="https://www.benzinga.com/25/05/45572375/my-top-big-tech-option-trade-of-the-week">My Top Big Tech Option Trade Of The Week</a>
<h2 class="wp-block-heading">How To Buy ADM Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Archer-Daniels-Midland&#8217;s case, it is in the Consumer Staples sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ADM has a 52-week high of $66.08 and a 52-week low of $40.98.

Archer-Daniels-Midland (ADM) Stock Slips As EU Tariff Threat Raises Retaliation Risk For US Agriculture

Stifel analyst Brad Reback maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Buy and raises the price target from $725 to $850.

INTU

Stifel Maintains Buy on Intuit, Raises Price Target to $850

Stifel analyst Brian Brophy maintains Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) with a Buy and raises the price target from $471 to $512.

Stifel Maintains Buy on Comfort Systems USA, Raises Price Target to $512

Barclays analyst Adrienne Yih maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Overweight and raises the price target from $260 to $321.

Barclays Maintains Overweight on Ralph Lauren, Raises Price Target to $321

<a href="https://www.bloomberg.com/news/articles/2025-05-23/douglas-elliman-gets-takeover-bid-amid-fallout-from-probe-of-former-star-agents?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-23/douglas-elliman-gets-takeover-bid-amid-fallout-from-probe-of-former-star-agents?embedded-checkout=true</a>

General

DOUG

'Douglas Elliman Gets Takeover Bid Amid Fallout From Probe of Former Star Agents'- Bloomberg

Stifel analyst Adam Borg maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Buy and raises the price target from $310 to $350.

ADSK

Stifel Maintains Buy on Autodesk, Raises Price Target to $350

Barclays analyst Raimo Lenschow maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Overweight and raises the price target from $775 to $815.

Barclays Maintains Overweight on Intuit, Raises Price Target to $815

<a href="https://x.com/laurentsmartin/status/1925921076787249344?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/laurentsmartin/status/1925921076787249344?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

Politics

Economics

French Minister Laurent Saint Martin Says Trump's Latest Tariffs Threat Are Unhelpful

U.S. stocks were lower, with the Dow Jones index falling around 300 points on Friday.
Shares of Frontline plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) rose during Friday's session <a href="https://www.benzinga.com/quote/FRO/earnings">following first-quarter results</a>.
The company reported revenue of $427.9 million, surpassing the $264.2 million consensus. Adjusted EPS declined to 18 cents from 62 cents a year ago, missing the consensus of 23 cents.
Frontline shares gained 3.7% to $17.81 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) shares jumped 30% to $54.04 as the company disclosed interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) rose 24.7% to $34.40.</li>
<li>Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) gained 23.4% to $114.98.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) rose 23.1% to $49.03 after Wedbush raised its price target on the stock from $45 to $55 and maintained an Outperform rating.</li>
<li>Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) gained 23.1% to $114.80.</li>
<li>Uranium Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UEC#NYSE">UEC</a>) gained 19.2% to $6.15.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) shares gained 16% to $29.36.</li>
<li>NexGen Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) rose 11.6% to $6.07.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) gained 8.8% to $724.54 after the company reported better-than-expected third-quarter financial results and raised guidance.</li>
<li>Cameco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) rose 8.2% to $57.13.</li>
<li>BWX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) gained 6.5% to $114.70.</li>
<li>Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) rose 5.4% to $39.61.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45585296/jim-cramer-says-medical-properties-trust-has-too-much-risk-likes-this-industrial-stock">Jim Cramer Says Medical Properties Trust Has &#8216;Too Much Risk,&#8217; Likes This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

Movers

BWXT

MRUS

Nuveen Arizona Dividend Advantage Municipal Funds 3

OKLO

Frontline, Merus, Intuit And Other Big Stocks Moving Higher On Friday

Press Releases

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

Health Care

Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System

Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target

Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market

Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study

Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device

Comments

Helius Medical Tech

空売り

Helius Medical Tech (NASDAQ:HSDT) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル